An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA.
(2010) In Journal of Internal Medicine 267. p.316-321- Abstract
- Abstract. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T, Groop L, Dahlbäck B, Karlsson E (Lund University, Malmö, Sweden, Steno Diabetes Center, Gentofte, Denmark, University of Helsinki; and Folkhälsan Research Centre, Helsinki, Finland). An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 2009; doi: 10.1111/j.1365-2796.2009.02145.x.Objective. To investigate the fitness of serum apolipoprotein M (apoM) concentration as a marker for maturity-onset diabetes of the young 3 (MODY3). Study design and subjects. This study consisted of two parts. A family study included 71 carriers of the P291fsinsC mutation in hepatocyte nuclear factor-1alpha (HNF-1alpha) from the Finnish... (More)
- Abstract. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T, Groop L, Dahlbäck B, Karlsson E (Lund University, Malmö, Sweden, Steno Diabetes Center, Gentofte, Denmark, University of Helsinki; and Folkhälsan Research Centre, Helsinki, Finland). An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 2009; doi: 10.1111/j.1365-2796.2009.02145.x.Objective. To investigate the fitness of serum apolipoprotein M (apoM) concentration as a marker for maturity-onset diabetes of the young 3 (MODY3). Study design and subjects. This study consisted of two parts. A family study included 71 carriers of the P291fsinsC mutation in hepatocyte nuclear factor-1alpha (HNF-1alpha) from the Finnish Botnia study, 53 of whom were diabetic, and 75 matched family controls. A second, case-control study included 24 MODY3 patients, 17 healthy MODY3 mutation carriers, 11 MODY1 patients, 18 type 2 diabetes patients and 19 healthy control individuals. Subjects in the case-control study were recruited from the Botnia study or the Clinic of Endocrinology, Malmö University Hospital. Serum apoM levels were measured using a novel ELISA based on two monoclonal apoM antibodies. Results. In the family study, mean serum apoM was 10% lower in female carriers of the P291fsinsC mutation compared to the family controls (P = 0.0058), a difference which remained significant after adjustment for diabetes status. There was no observed difference between groups for men. In the case-control study, no significant difference in apoM concentration was observed between MODY3 and type 2 diabetes patients, neither before nor after adjustment for total cholesterol. Conclusions. Female carriers of the P291fsinsC mutation in HNF-1alpha displayed slightly lower apoM serum levels. This difference is too small for apoM to be reliably employed as a biomarker for HNF-1alpha mutation status. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1483491
- author
- Cervin, Camilla LU ; Axler, Olof LU ; Holmkvist, Johan LU ; Almgren, Peter LU ; Rantala, E ; Tuomi, Tiinamaija LU ; Groop, Leif LU ; Dahlbäck, Björn LU and Ekholm, Ella LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Internal Medicine
- volume
- 267
- pages
- 316 - 321
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000274184400008
- pmid:19754856
- scopus:75749155017
- pmid:19754856
- ISSN
- 1365-2796
- DOI
- 10.1111/j.1365-2796.2009.02145.x
- language
- English
- LU publication?
- yes
- id
- 8658b61d-0526-446f-a5fc-f40d2c136f83 (old id 1483491)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19754856?dopt=Abstract
- date added to LUP
- 2016-04-04 09:27:46
- date last changed
- 2024-01-12 13:50:30
@article{8658b61d-0526-446f-a5fc-f40d2c136f83, abstract = {{Abstract. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T, Groop L, Dahlbäck B, Karlsson E (Lund University, Malmö, Sweden, Steno Diabetes Center, Gentofte, Denmark, University of Helsinki; and Folkhälsan Research Centre, Helsinki, Finland). An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 2009; doi: 10.1111/j.1365-2796.2009.02145.x.Objective. To investigate the fitness of serum apolipoprotein M (apoM) concentration as a marker for maturity-onset diabetes of the young 3 (MODY3). Study design and subjects. This study consisted of two parts. A family study included 71 carriers of the P291fsinsC mutation in hepatocyte nuclear factor-1alpha (HNF-1alpha) from the Finnish Botnia study, 53 of whom were diabetic, and 75 matched family controls. A second, case-control study included 24 MODY3 patients, 17 healthy MODY3 mutation carriers, 11 MODY1 patients, 18 type 2 diabetes patients and 19 healthy control individuals. Subjects in the case-control study were recruited from the Botnia study or the Clinic of Endocrinology, Malmö University Hospital. Serum apoM levels were measured using a novel ELISA based on two monoclonal apoM antibodies. Results. In the family study, mean serum apoM was 10% lower in female carriers of the P291fsinsC mutation compared to the family controls (P = 0.0058), a difference which remained significant after adjustment for diabetes status. There was no observed difference between groups for men. In the case-control study, no significant difference in apoM concentration was observed between MODY3 and type 2 diabetes patients, neither before nor after adjustment for total cholesterol. Conclusions. Female carriers of the P291fsinsC mutation in HNF-1alpha displayed slightly lower apoM serum levels. This difference is too small for apoM to be reliably employed as a biomarker for HNF-1alpha mutation status.}}, author = {{Cervin, Camilla and Axler, Olof and Holmkvist, Johan and Almgren, Peter and Rantala, E and Tuomi, Tiinamaija and Groop, Leif and Dahlbäck, Björn and Ekholm, Ella}}, issn = {{1365-2796}}, language = {{eng}}, pages = {{316--321}}, publisher = {{Wiley-Blackwell}}, series = {{Journal of Internal Medicine}}, title = {{An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA.}}, url = {{http://dx.doi.org/10.1111/j.1365-2796.2009.02145.x}}, doi = {{10.1111/j.1365-2796.2009.02145.x}}, volume = {{267}}, year = {{2010}}, }